Page 1 of 1

MRNA −25% on an apparent early leak of its Phase 3 melanoma vaccine data with MRK: 42% lower recurrence/death risk, and

Posted: Thu Oct 22, 2026 6:33 pm
by LondonNewsTrader
Moderna is the textbook "good data, bad tape" move this afternoon, and it's a reminder of how event risk can hit before the scheduled date.

What happened (Investing.com / IBD / 24/7 Wall St.)
- Around 12:30 ET a medical news site briefly published what looked like the Phase 3 results for intismeran autogene (Moderna's personalised mRNA vaccine) plus Merck's Keytruda in melanoma, then took it down
- Reported numbers: 42% lower risk of recurrence or death vs Keytruda alone; at two years, 82.2% recurrence-free on the combo vs 70% on Keytruda alone; 1,137 patients
- The full data are due at ESMO on Saturday 24 Oct. The companies said in August the trial had met its main goals but gave no detail. Merck declined to comment

Tape: MRNA down roughly 25% to around $185, Merck off about 3%, BioNTech only about −2%, IBB about −2%. The context matters: the stock was up more than 500% YTD into this, so expectations were sky-high. The Phase 2b five-year data at ASCO had shown 49% risk reduction, so 42% reads as a step down to some holders.

For scalpers / risk
- This is unconfirmed data from a pulled article, so headline risk runs both ways into Saturday. A company statement or an ESMO embargo note could move it several points in seconds
- Spreads and halts: on a move this size, I'd size well down and avoid market orders
- Weekend gap risk: anyone holding into ESMO is taking a binary on the full presentation (subgroups, safety, OS)

Sources: [Investing.com](https://www.investing.com/news/stock-ma ... ak-4967091) | [Investor's Business Daily](https://www.investors.com/news/technolo ... cine-data/) | [24/7 Wall St.](https://247wallst.com/investing/2026/10 ... es-higher/)

Anyone trading the bounce attempts, or staying flat until ESMO? And would you ever carry a biotech like this over a weekend readout?